Step Pharma SAS
Step Pharma is a clinical stage precision oncology company. Dencatistat (STP938) is a first in class, oral, selective CTPS1 inhibitor currently in Phase I/II clinical development in essential thrombocythemia, biomarker selected solid tumours and relapsed/refractory lymphoma.
Date, time and room information
Tuesday, May 5, 14:45 - 15:00, room Montreal
Category
Clinical stage development company
Title of the presentation
Step Pharma
Speaker information
| Name | Position | Institution |
|---|---|---|
| Andrew Edward Parker | CEO | Step Pharma SAS |
